Literature DB >> 10718620

Deferiprone (L1) induced conformation change of hemoglobin: A fluorescence and CD spectroscopic study.

D Chakraborty1, M Bhattacharyya.   

Abstract

The interaction of deferiprone (1,2-dimethyl-3-hydroxy-pyrid-4-one) L1, the first clinically available oral iron chelator, with the tetrameric allosteric protein hemoglobin from human red blood cells has been investigated spectrofluorometrically and by circular dichroism spectroscopy. The interaction is hydrogenbond like electrostatic in nature, the binding constant being 4.54 x 10(3) M(-1) in 0.15 M NaCl. Circular dichroism studies indicate a conformational change of hemoglobin in presence of deferiprone, helicity of hemoglobin being reduced in presence of increasing concentration of the drug L1.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10718620     DOI: 10.1023/a:1007049701572

Source DB:  PubMed          Journal:  Mol Cell Biochem        ISSN: 0300-8177            Impact factor:   3.396


  10 in total

Review 1.  Development of iron-chelating agents for clinical use.

Authors:  G M Brittenham
Journal:  Blood       Date:  1992-08-01       Impact factor: 22.113

Review 2.  Mechanisms regulating the reactions of human hemoglobin with oxygen and carbon monoxide.

Authors:  M F Perutz
Journal:  Annu Rev Physiol       Date:  1990       Impact factor: 19.318

3.  Determination of the secondary structures of proteins by circular dichroism and optical rotatory dispersion.

Authors:  Y H Chen; J T Yang; H M Martinez
Journal:  Biochemistry       Date:  1972-10-24       Impact factor: 3.162

4.  Development of oral iron chelator L1.

Authors:  C Hershko
Journal:  Lancet       Date:  1993-04-24       Impact factor: 79.321

5.  Long-term trial with the oral iron chelator 1,2-dimethyl-3-hydroxypyrid-4-one (L1). II. Clinical observations.

Authors:  A N Bartlett; A V Hoffbrand; G J Kontoghiorghes
Journal:  Br J Haematol       Date:  1990-10       Impact factor: 6.998

6.  Salivary measurement of deferiprone concentrations and correlation with serum levels.

Authors:  E Pope; M Berkovitch; J Klein; F Fassos; G Koren
Journal:  Ther Drug Monit       Date:  1997-02       Impact factor: 3.681

7.  Protein-ligand interactions: interaction of nitrosamines with nicotinic acetylcholine receptor.

Authors:  E A Kapp; S Daya; C G Whiteley
Journal:  Biochem Biophys Res Commun       Date:  1990-03-30       Impact factor: 3.575

8.  Evidence for cooperative binding of chlorpromazine with hemoglobin: equilibrium dialysis, fluorescence quenching and oxygen release study.

Authors:  M Bhattacharyya; U Chaudhuri; R K Poddar
Journal:  Biochem Biophys Res Commun       Date:  1990-03-30       Impact factor: 3.575

9.  Deferiprone (L1) chelates pathologic iron deposits from membranes of intact thalassemic and sickle red blood cells both in vitro and in vivo.

Authors:  O Shalev; T Repka; A Goldfarb; L Grinberg; A Abrahamov; N F Olivieri; E A Rachmilewitz; R P Hebbel
Journal:  Blood       Date:  1995-09-01       Impact factor: 22.113

10.  A multi-center safety trial of the oral iron chelator deferiprone.

Authors:  A Cohen; R Galanello; A Piga; C Vullo; F Tricta
Journal:  Ann N Y Acad Sci       Date:  1998-06-30       Impact factor: 5.691

  10 in total
  3 in total

1.  Deferiprone: structural and functional modulating agent of hemoglobin fructation.

Authors:  Naghmeh Sattarahmady; Hossein Heli; Ali A Moosavi-Movahedi; K Karimian
Journal:  Mol Biol Rep       Date:  2014-01-11       Impact factor: 2.316

2.  Microscale Thermophoresis and Molecular Modelling to Explore the Chelating Drug Transportation in the Milk to Infant.

Authors:  Mufarreh Asmari; Muhammad Waqas; Adel Ehab Ibrahim; Sobia Ahsan Halim; Ajmal Khan; Ahmed Al-Harrasi; Hermann Wätzig; Sami El Deeb
Journal:  Molecules       Date:  2022-07-19       Impact factor: 4.927

Review 3.  Iron and Chelation in Biochemistry and Medicine: New Approaches to Controlling Iron Metabolism and Treating Related Diseases.

Authors:  George J Kontoghiorghes; Christina N Kontoghiorghe
Journal:  Cells       Date:  2020-06-12       Impact factor: 6.600

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.